Skip to content

Effects of Levothyroxine on lipid profile in subclinical hypothyroidism

Effects of Levothyroxine treatment on lipid profile in subclinical hypothyroidism

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903244179N1
Enrollment
90
Registered
2010-10-14
Start date
2010-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinicsl Hypothyroidism. Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention 1: Levothyroxine 50-75 microgram daily/ orally for 3 months. Intervention 2: Placebo 1/2- 3/4 tab daily/ orally.
Treatment - Drugs
Placebo
Levothyroxine 50-75 microgram daily/ orally for 3 months
Placebo 1/2- 3/4 tab daily/ orally

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: High TSH with FT4 in normal range Exclusion criteria: receiving levothyroxine, glucocorticoids, asprin, amiodaron, lipid lowering agents, OCP, dopamine antagonist eg. metoclopramide or domperidone in 6 months prior to the study, presence of diabetes mellitus, pregnancy, menopause, age older than 60 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Triglyceride. Timepoint: Baseline and 3 months after the intervention. Method of measurement: photometery.;Cholestrol. Timepoint: Baseline and 3 months after the intervention. Method of measurement: photometery.;LDL. Timepoint: Baseline and 3 months after the intervention. Method of measurement: photometery.;HDL. Timepoint: Baseline and 3 months after the intervention. Method of measurement: photometery.;Lp(a). Timepoint: Baseline and 3 months after the intervention. Method of measurement: biochemistry.

Secondary

MeasureTime frame
TSH. Timepoint: Baseline and 3 months after the intervention. Method of measurement: chemiluminescence.;FT4. Timepoint: Baseline and 3 months after the intervention. Method of measurement: chemiluminescence.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Karoon Shahebrahimi

Emam Reza hospital

dr-Shahebrahimi@Yahoo.Com+98 83 1427 6309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026